Oxis Biotech, Inc. (Oxis)

Oncology Corporate Profile

HQ Location

4830 West Kennedy Blvd
Tampa, FL 33609

Company Description

Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL), is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.

Website: http://www.oxis.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
OXS-1550bispecific scFv recombinant fusion proteinNon-Hodgkin's Lymphoma (NHL)I

View additional information on product candidates here »

Source: http://www.oxis.com

Recent News Headlines

7/25/2017 12:31 am

7/25/2017 12:31 am

7/25/2017 12:31 am

7/25/2017 12:31 am

7/25/2017 12:31 am

7/5/2017 06:19 am

7/5/2017 06:19 am

7/5/2017 06:19 am

7/5/2017 06:19 am

7/5/2017 06:19 am

6/26/2017 06:19 am

6/26/2017 06:19 am

6/26/2017 06:19 am

6/26/2017 06:19 am

6/26/2017 06:19 am

6/13/2017 06:19 am

6/13/2017 06:19 am

6/13/2017 06:19 am

6/13/2017 06:19 am

6/13/2017 06:19 am

5/3/2017 06:18 am

4/18/2017 06:19 am

Oxis International Enters into a Sponsored Research Agreement with the University of Minnesota

3/23/2017 12:00 pm

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / March 23, 2017 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that it has entered into a sponsored research agreement with the University ...